Literature DB >> 7913097

Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey.

F McOmish1, P L Yap, B C Dow, E A Follett, C Seed, A J Keller, T J Cobain, T Krusius, E Kolho, R Naukkarinen.   

Abstract

The frequency of infection with the six classified major genotypes of hepatitis C virus (HCV) was investigated in 447 infected volunteer blood donors from the following nine countries: Scotland, Finland, The Netherlands, Hungary, Australia, Egypt, Japan, Hong Kong, and Taiwan. Viral sequences in plasma from blood donors infected with HCV were amplified in the 5'-noncoding region and were typed by restriction fragment length polymorphism analysis. Electrophoresis of DNA fragments produced by cleavage with HaeIII-RsaI and ScrFI-HinfI allowed HCV types 1 (or 5), 2, 3, 4, and 6 to be identified. Further analysis with MvaI-HinfI allowed sequences of the type 5 genotype to be distinguished from sequences of the type 1 genotype. Types 1, 2, and 3 accounted for almost all infections in donors from Scotland, Finland, The Netherlands, and Australia. Types 2 and 3 were not found in the eastern European country (Hungary), where all but one of the donors were infected with type 1. Donors from Japan and Taiwan were infected only with type 1 or 2, while types 1, 2, and 6 were found in those from Hong Kong. HCV infection among Egyptians was almost always by type 4. Donors infected with HCV type 1 showed broad serological reactivity with all four antigens of the second generation Chiron RIBA-2 assay (Chiron Corporation, Emeryville, Calif.), while infection with divergent HCV genotypes elicited antibodies mainly reactive to c22-3 and c33c. Reactivities with antibodies 5-1-1 and c100-3 were infrequent and were generally weak, irrespective of the geographical origin of the donor. Because the envelope region of HCV is even more variable than the NS-4 region, it is likely that vaccines based on these proteins need to be multivalent and perhaps specifically adapted for different geographical regions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913097      PMCID: PMC263157          DOI: 10.1128/jcm.32.4.884-892.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Serological responses to infection with three different types of hepatitis C virus.

Authors:  S W Chan; P Simmonds; F McOmish; P L Yap; R Mitchell; B Dow; E Follett
Journal:  Lancet       Date:  1991-11-30       Impact factor: 79.321

3.  Distribution of plural HCV types in Japan.

Authors:  N Kato; Y Ootsuyama; S Ohkoshi; T Nakazawa; S Mori; M Hijikata; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1991-11-27       Impact factor: 3.575

Review 4.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

5.  Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions.

Authors:  H Okamoto; S Okada; Y Sugiyama; K Kurai; H Iizuka; A Machida; Y Miyakawa; M Mayumi
Journal:  J Gen Virol       Date:  1991-11       Impact factor: 3.891

6.  Confirmation of hepatitis C virus antibody in blood donors.

Authors:  B C Dow; I Coote; H Munro; F McOmish; P L Yap; P Simmonds; E A Follett
Journal:  J Med Virol       Date:  1993-11       Impact factor: 2.327

7.  There are two major types of hepatitis C virus in Japan.

Authors:  N Enomoto; A Takada; T Nakao; T Date
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

8.  Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.

Authors:  J I Esteban; A González; J M Hernández; L Viladomiu; C Sánchez; J C López-Talavera; D Lucea; C Martin-Vega; X Vidal; R Esteban
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

9.  Typing of hepatitis C virus genomes by restriction fragment length polymorphism.

Authors:  T Nakao; N Enomoto; N Takada; A Takada; T Date
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

10.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

View more
  109 in total

1.  Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy.

Authors:  P Dentico; N Curatolo; R Sacco; M De Luca; A Volpe; C Ranieri; C Genchi; L Petracca; R Buongiorno
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

2.  Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance.

Authors:  Matthias Schröter; Bernhard Zöllner; Peter Schäfer; Andreas Reimer; Matthias Müller; Rainer Laufs; Heinz-Hubert Feucht
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

3.  Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

Review 4.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

5.  Predominance of hepatitis C virus genotype 1b in Bulgaria.

Authors:  A Andonov; P Teoharov; S Bakalova
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

6.  Assessment of commercial enzyme immunoassay for hepatitis C virus serotyping.

Authors:  L M Webber; S Els; M B Taylor; W O Grabow
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Concordance of hepatitis C virus typing methods based on restriction fragment length polymorphism analysis in 5' noncoding region and NS4 serotyping, but not in core PCR or a line probe assay.

Authors:  S Navas; I Castillo; J Martín; J A Quiroga; J Bartolomé; V Carreño
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

9.  Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assay patterns.

Authors:  J M Pawlotsky; F Roudot-Thoraval; C Pellet; P Aumont; F Darthuy; J Remire; J Duval; D Dhumeaux
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

10.  Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients.

Authors:  E Villa; P Buttafoco; A Merighi; A Grottola; I Ferretti; A Ferrari; F Callea; P Trande; A M Rebecchi; F Manenti
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.